What was the market valuation of immunotherapy drugs in Germany in 2024?

The market valuation of immunotherapy drugs in Germany was $6.02 Billion in 2024. Read More

What is the projected market valuation for immunotherapy drugs in Germany by 2035?

The projected market valuation for immunotherapy drugs in Germany is $12.6 Billion by 2035. Read More

What is the expected CAGR for the Germany immunotherapy drugs market during the forecast period 2025 - 2035?

The expected CAGR for the Germany immunotherapy drugs market during the forecast period 2025 - 2035 is 6.95%. Read More

Which therapeutic area is expected to have the highest growth in the immunotherapy drugs market?

Oncology is expected to have the highest growth, with a projected increase from $2.5 Billion to $5.2 Billion. Read More

How much is the market for autoimmune disorder immunotherapy drugs projected to grow by 2035?

The market for autoimmune disorder immunotherapy drugs is projected to grow from $1.2 Billion to $2.5 Billion by 2035. Read More

What is the expected growth for the vaccines segment in the immunotherapy drugs market?

The vaccines segment is expected to grow from $1.2 Billion to $2.52 Billion by 2035. Read More

Which route of administration is anticipated to dominate the immunotherapy drugs market?

The intravenous route of administration is anticipated to dominate, with growth from $2.41 Billion to $5.04 Billion. Read More

What is the projected growth for the pharmaceutical companies as end users in the immunotherapy drugs market?

The pharmaceutical companies segment is projected to grow from $2.4 Billion to $5.02 Billion by 2035. Read More

How does the growth of checkpoint inhibitors compare to other drug types in the market?

Checkpoint inhibitors are expected to grow from $1.81 Billion to $3.78 Billion, indicating robust growth compared to other drug types. Read More

Germany Immunotherapy Drugs Market

Q: What are the key players in the Germany immunotherapy drugs market?

Key players in the market include Bristol-Myers Squibb, Merck & Co, Roche, Novartis, Amgen, Gilead Sciences, AstraZeneca, Pfizer, and Eli Lilly and Company. Read More

ID: MRFR/Pharma/52094-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

Germany Immunotherapy Drugs Market Research Report By Therapeutic Area (Oncology, Autoimmune Disorders, Infectious Diseases, Allergy), By Drug Type (Monoclonal Antibodies, Checkpoint Inhibitors, Vaccines, Cytokines), By Route of Administration (Intravenous, Subcutaneous, Oral) and By End User (Hospitals, Research Institutions, Pharmaceutical Companies) - Growth & Industry Forecast 2025 To 2035

Germany Immunotherapy Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.95%

2024 Market Size$ 6.02 Billion

2025 Market Size$ 6.44 Billion

2035 Market Size$ 12.6 Billion

Key Players

Bristol-Myers Squibb

Merck & Co

Roche

Novartis

Amgen

Gilead Sciences

Trends

Increased Investment in Research and Development
Regulatory Support for Innovative Therapies
Focus on Personalized Medicine

Opportunities

Rising Cancer Incidence
Regulatory Framework Enhancements
Increased Funding for Cancer Research

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Therapeutic Area (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Disorders
  3. 4.1.3 Infectious Diseases
  4. 4.1.4 Allergy
2. 4.2 Pharmaceutical, BY Drug Type (USD Billion)
  1. 4.2.1 Monoclonal Antibodies
  2. 4.2.2 Checkpoint Inhibitors
  3. 4.2.3 Vaccines
  4. 4.2.4 Cytokines
3. 4.3 Pharmaceutical, BY Route of Administration (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
4. 4.4 Pharmaceutical, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Research Institutions
  3. 4.4.3 Pharmaceutical Companies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Gilead Sciences (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
3. 6.3 GERMANY MARKET ANALYSIS BY DRUG TYPE
4. 6.4 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 GERMANY MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
14. 6.14 PHARMACEUTICAL, BY DRUG TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  2. 7.2.2 BY DRUG TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Germany Immunotherapy Drugs Market Segmentation

Germany Immunotherapy Drugs Market By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Autoimmune Disorders
Infectious Diseases
Allergy

Germany Immunotherapy Drugs Market By Drug Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Checkpoint Inhibitors
Vaccines
Cytokines

Germany Immunotherapy Drugs Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Oral

Germany Immunotherapy Drugs Market By End User (USD Billion, 2025-2035)

Hospitals
Research Institutions
Germany Immunotherapy Drugs Market Companies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”